AzTrials
AzTrials

HealthyNCT06806501

Muscle Mass, Quality, and the Menopause: Sex-specific Strategies to Mitigate Sarcopenia in Ageing Populations

An observational study of Healthy, run by University of Nottingham at 1 site in United Kingdom.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Aging causes muscles to often become smaller and weaker resulting in physical frailty and functional impairments, such as difficulty raising from a chair, dressing, and preparing meals. In the UK there is a growing aged population with those >65y expected to increase from 18% of the population in 2016, to 26% by 2066. Read more about this study

Who is it for?
Ages 18 to 65 years, women onlyHealthy volunteers can take part
Conditions the study is for
Healthy
What is being tested?
Unilateral Resistance Exercise
How many people
18 participants
Where
1 siteUnited Kingdom
Study dates
29 Jul 2024to Mar 2026
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • Women only
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Participants will be healthy females aged 18 - 65, who are not on hormonal replacement therapy or hormonal contraceptives and are not participating in regular resistance exercise. Participants will fall into two groups: * Premenopausal, defined as having a menstrual cycle and having plasma follicle-stimulating hormone (FSH) <30 IU/L, taken during days 1-5 of their menstrual cycle. * Postmenopausal, defined as having no menses for 12 months, E2 (Oestradiol) < 118pmol/L and FSH >30 IU/L.

Who may be able to join

  • Biological woman, 18-65 years of age
  • Body mass index (BMI) 18-30 kg/m2
  • Non smoker
  • Not performing regular resistance type exercise
  • Participant is willing and able to give informed consent for participation in the study

Who cannot join

  • A BMI <18 or >39 kg·m-2
  • Active cardiovascular disease: uncontrolled hypertension (Blood pressure > 160/100), angina, heart failure (class III/IV), arrhythmia, right to left cardiac shunt or recent cardiac event.
  • Cerebrovascular disease: previous stroke, aneurysm (large vessel or intracranial)
  • Respiratory disease including pulmonary hypertension or Chronic obstructive pulmonary disease (COPD).
  • Metabolic disease: hyper and hypo parathyroidism, untreated hyper and hypothyroidism, Cushing's disease, types 1 or 2 diabetes (treated and untreated), polycystic ovarian syndrome (PCOS), inborn/ congenital errors of metabolism (e.g. Phenylketonuria (PKU), galactosaemia)
  • Active inflammatory bowel disease.
Show all 17Show fewer
  • Acute infection.
  • Acute or chronic renal disease.
  • Malignancy (or history of malignancy with 5 y).
  • Recent (within 6 mo) or current steroid treatment, hormone replacement therapy (HRT), hormonal contraception, or other hormonal therapies that may interfere with outcome measures.
  • Coagulopathy.
  • Musculoskeletal or neurological disorders.
  • Having taken part in a research study in the last 3 months involving invasive procedures or an inconvenience allowance.
  • Amenorrhoea for a reason other than menopause.
  • Contraindications for Magnetic Resonance Imaging (MRI).
  • Allergy or sensitivity to local anaesthesia, or dressing adhesive.
  • Inner ear pathology or vertigo

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

United Kingdom1 site, 1 recruiting
  • Queens Medical Centre Campus

    Nottingham

    Matthew Brook, 0115 8230248, Matthew.Brook@nottingham.ac.uk

    Matthew Brook, PhD

    Recruiting

Other trials in United Kingdom

About this study

Aging causes muscles to often become smaller and weaker resulting in physical frailty and functional impairments, such as difficulty raising from a chair, dressing, and preparing meals. In the UK there is a growing aged population with those >65y expected to increase from 18% of the population in 2016, to 26% by 2066. As such, age related muscle mass loss and functional impairments represents one of the largest problems facing the health care services. There is an urgent need to develop strategies to reduce healthcare costs and improve health and wellbeing with age. These strategies must be targeted, as evidence suggests that the loss in muscle size and strength is different between men and women throughout the aging process. For example, older women have greater levels of physical disability that includes difficulties in walking around the home, getting out of a bed or chair, and eating, compared with men. These sex differences with ageing are unclear, yet the greater levels of physical disability could be the result of the menopause. The menopause describes a change in the sex hormone environment that is a part of normal female ageing. Physical disability can be further enhanced by an increase in body fat during the menopause in the face of decreasing muscle mass. Currently, there is a lack of understanding as to how these changes in body composition occur, with no effective treatments against muscle mass loss. The aims of this project are to increase understanding on how the menopause impacts muscle mass regulation. In addition, the investigators will use novel magnetic resonance imaging (MRI) techniques to map the distribution of newly created fat, and qualitative interviews to better understand how resistance exercise therapy (RET) can be incorporated into the daily lives of postmenopausal women.

Read the detailed description

The age-related loss of muscle mass and function (sarcopenia) inevitably results in physical frailty and functional impairments, such as difficulty raising from a chair, dressing, and preparing meals. With a rapidly growing aged population (those >65y increasing from 18% of the population in 2016, to 26% by 2066), sarcopenia represents one of the largest problems facing health care services. Excess healthcare costs associated with sarcopenia are rapidly growing and were estimated to be £2.5 billion in 2016. There is an urgent need to develop strategies to mitigate sarcopenia to reduce healthcare costs and improve health and wellbeing with age. These strategies must be targeted, as evidence suggests that there is sexual dimorphism in ageing and the development of sarcopenia. Sarcopenia develops earlier in women, resulting in greater levels of physical disability that includes difficulties in walking, getting out of a chair, and eating, compared with men. The mechanistic sex differences with ageing are unclear, yet the earlier prevalence of sarcopenia in women coincides with the menopause. In addition, physical disability can be further exacerbated by an increase in adiposity during the menopause in the face of decreasing muscle mass. This change in body composition includes ectopic fat infiltration into muscle that is associated with decreased muscle performance, however, currently, there is a lack of understanding as to how these changes in body composition occur.

Understanding the underlying mechanisms that bring about change in physiological systems is key in the development of interventions. Muscle mass is controlled by the balance between muscle protein synthesis (MPS) and muscle protein breakdown (MPB). With age, many of the signals that increase MPS (i.e., nutrient intake and activity) become less effective, resulting in negative protein balance and muscle loss. Since muscle loss is accelerated after the menopause in women, there must be a greater imbalance between MPS and MPB. The measurement of MPS and MPB can be achieved using stable isotope tracer techniques that can be followed throughout the body. However, there is a lack of research into the mechanistic effects of the menopause on muscle mass regulation. In addition to measures of muscle protein turnover, the investigators have recently used stable isotope tracer techniques alongside MRI scanning to image deuterium incorporation within lipid. the investigators will use these techniques to image newly created fat to further understanding of body composition changes in post-menopausal women.

Resistance exercise therapy (RET) currently offers the most effective strategy to mitigate muscle mass loss and improve body composition with ageing, by increasing MPS, promoting muscle hypertrophy, and building strength8. However, older women display blunted muscle hypertrophy in response to RET (when compared to younger women, and older men), and it is not known how the menopause affects hypertrophic responses to exercise. Further, for any intervention to have a meaningful impact, it must be effectively incorporated by postmenopausal women into their daily lives. The investigators have conducted an evaluation of physical activity interventions for post-menopausal women, which revealed that women going through the menopause want more evidence-based guidance on how much and what type of exercise they should be doing, and on whether exercise can alleviate menopausal symptoms and prevent muscle loss.

Aims: To investigate the effects of the menopause on muscle mass regulation, changes in body composition, and assess the acceptability and effectiveness of RET.

Conditions
Healthy
Being tested
Unilateral Resistance Exercise

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Unilateral Resistance ExerciseBehavioural

    Resistance exercise training session, consisting of 6 x 8 repetitions of leg extension (of the non-dominant leg) at 75% 1RM (repetition maximum) with 2 min rest between sets.

Study groups in NCT06806501
Study groupRoleWhat they receive
PremenopausalDefined as having a menstrual cycle and having plasma follicle-stimulating hormone (FSH) <30 IU/L, taken during days 1-5 of their menstrual cycle.
Receives: Behavioral: Unilateral Resistance Exercise
PostmenopausalDefined as having no menses for 12 months, E2 (Oestradiol) < 118pmol/L and FSH >30 IU/L.
Receives: Behavioral: Unilateral Resistance Exercise

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Rate of muscle protein synthesis

    Comparison between pre and post menopausal women of vastus lateralis muscle protein synthesis in response to acute unilateral resistance exercise and at rest using deuterium oxide stable isotope techniques.

    Measured: 3 Days

  2. Rate of muscle protein breakdown

    Comparison between pre and post menopausal women of whole body muscle protein breakdown in response to acute unilateral resistance exercise and at rest using D3-3-methylhistidine

    Measured: 3 Days

Secondary outcomes (7)
  1. Whole body muscle mass

    Comparison between pre and post menopausal women of whole body muscle mass using D3-Creatine

    Measured: At the point of enrolment

  2. Quadriceps fat mass

    Comparison between pre and post menopausal women of quadriceps fat using Dixon magnetic resonance imaging (MRI) of the quadriceps

    Measured: At the point of enrolment

  3. Menopausal symptoms

    Comparison between pre and post menopausal women of menopausal symptoms on the menopause rating scale (0 - 44; higher score = greater menopause symptoms)

    Measured: At the point of enrolment

  4. Knee extensor strength

    Comparison between pre and post menopausal women of knee extensor muscle strength in response to unilateral exercise training using a cybex dynamometer

    Measured: At the point of enrolment

  5. De novo lipogenesis

    Use deuterium magnetic resonance imaging (MRI) to map the distribution of newly created lipid in pre and post menopausal women.

    Measured: 0 - 8 weeks

  6. Intramuscular protein signalling

    Comparison between pre and post menopausal women of intramuscular protein signalling in response to unilateral resistance exercise using immunoblotting.

    Measured: 0 - 3 Days

  7. Muscle gene expression

    Comparison between pre and post menopausal women of muscle messenger ribonucleic acid (mRNA) gene expression in response to unilateral resistance exercise using polymerase chain reactions (PCR).

    Measured: 0 - 3 Days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Feb 2025
  2. Study start29 Jul 2024
  3. Primary completionMar 2026 (estimated)
  4. Study completionMar 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Cross-sectional
Enrolment
18 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06806501
Sponsor's protocol ID
FMHS 129-0224
Status last verified
Jan 2025
First submitted
18 Jun 2024
Last updated
4 Feb 2025
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Healthy, run by University of Nottingham at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 4 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Matthew Brook (0115 8230248, Matthew.Brook@nottingham.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Rate of muscle protein synthesis (time frame: 3 Days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Feb 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in